Abstract:No FDA or EMA approved therapies exist for bleeding due to hereditary hemorrhagic telangiectasia (HHT), the second-most-common inherited bleeding disorder worldwide. The current standard-of-care (SOC) includes iron and red cell supplementation, alongside the necessary hemostatic procedures, none of which target underlying disease pathogenesis. Recent evidence has demonstrated that bleeding pathophysiology is amenable to systemic antiangiogenic therapy with the anti-VEGF bevacizumab. Despite its high cost, the addition of longitudinal bevacizumab to the current SOC may reduce overall healthcare resource utilization and improve patient quality-of-life. We conducted the first cost-effectiveness analysis of IV bevacizumab in patients with HHT with the moderate-to-severe phenotype, comparing 1) bevacizumab added to SOC versus 2) SOC alone. The primary outcome was the incremental net monetary benefit (iNMB) reported over a lifetime time horizon and across accepted willingness-to-pay thresholds, in USD per quality-adjusted-life-year (QALY). Bevacizumab therapy accrued 9.3 QALYS while generating 699,000 in costs accrued in the SOC strategy. The iNMB of bevacizumab therapy versus the standard of care was $433,000. No parameter variation and no scenario analysis, including choice of iron supplementation product, changed the outcome of bevacizumab being a cost-saving strategy. Bevacizumab therapy also saved patients an average of 133 hours spent receiving HHT-specific care per year of life. In probabilistic sensitivity analysis, bevacizumab was favored in 100% of all 10,000 Monte Carlo iterations across base-case and all scenario analyses. Bevacizumab should be considered for more favorable formulary placement in the care of patients with moderate-to-severe HHT.

S3648 Role of Bevacizumab in Hereditary Hemorrhagic Telangiectasia Associated Recurrent Gastrointestinal Bleeding: A Case Report

S3752 From Crisis to Control: Impact of Bevacizumab in Refractory GI Bleed in Hereditary Hemorrhagic Telangiectasia

Surgical Extraction in a Patient with Hereditary Hemorrhagic Telangiectasia - A Case Report

S3661 The Perpetual Hemorrhage: Managing Recurrent Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia

Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia

Medical and Interventional Management of Hereditary Hemorrhagic Telangiectasia

Glanzmann's thrombasthenia associated with gastrointestinal angiodysplasias successfully treated with bevacizumab

Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia

Hereditary hemorrhagic telangiectasia involving portal venous system: A case report and review of the literature

Hereditary Hemorrhagic Telangiectasia: A Pediatric-Focused Review

How I Treat Bleeding in Hereditary Hemorrhagic Telangiectasia

Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis

Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances

Severe Esophageal Bleeding in Colorectal Cancer Due to Antitumor Therapy: A Case Report

A case report of acute myocardial infarction with hereditary hemorrhagic telangiectasia

Hepatic manifestations of hereditary haemorrhagic telangiectasia

Pro-angiogenic changes of T-helper lymphocytes in hereditary hemorrhagic telangiectasia

Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management

Severe thrombocytopenia associated to bevacizumab in a patient with scleroderma, gastrointestinal angiodysplasias and refractory gastrointestinal bleeding

Hereditary hemorrhagic telangiectasia – pediatric review

Hereditary haemorrhagic telangiectasia: A primer for the paediatrician